Featured on MIT Technology Review: The race to find a covid-19 drug in the blood of survivors

“AbCellera’s microfluidic technology captures individual B cells from a blood sample and segregates them into micro-chambers, where they can be probed 200,000 at a time. A single experiment can determine which of those cells are making antibodies capable of most strongly attaching to the spike protein of the coronavirus, which it uses to enter human cells.”

Read full coverage on MIT Technology Review.


Together we can make game-changing discoveries.